ArticleMicrobial cell factories2015
Identification of novel tylosin analogues generated by a wblA disruption mutant of Streptomyces ansochromogenes.
Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- NewTheScientificWorldJournal · 2025Pooled it
- Actinobacteria: Smart Micro-Factories for The Health Sector.Recent patents on biotechnology · 2025Review
- Transcriptional regulators of secondary metabolite biosynthesis in Streptomyces.World journal of microbiology & biotechnology · 2024Review
- Multi-omics Data Reveal the Effect of Sodium Butyrate on Gene Expression and Protein Modification in Streptomyces.Genomics, proteomics & bioinformatics · 2023Article
- An efficient method for targeted cloning of large DNA fragments from Streptomyces.Applied microbiology and biotechnology · 2023Article
- An intricate regulation of WblA controlling production of silent tylosin analogues and abolishment of expressible nikkomycin.Science China. Life sciences · 2023Article
- A visualization reporter system for characterizing antibiotic biosynthetic gene clusters expression with high-sensitivity.Communications biology · 2022Article
- Genetic Engineering ofMicroorganisms · 2021Article
- Activation of Cryptic Antibiotic Biosynthetic Gene Clusters Guided by RNA-seq Data from BothAntibiotics (Basel, Switzerland) · 2021Article
- WblA, a global regulator of antibiotic biosynthesis in Streptomyces.Journal of industrial microbiology & biotechnology · 2021Review
- Secondary nucleotide messenger c-di-GMP exerts a global control on natural product biosynthesis in streptomycetes.Nucleic acids research · 2020Article
- Co-expression of a SARP Family Activator ChlF2 and a Type II Thioesterase ChlK Led to High Production of Chlorothricin inFrontiers in bioengineering and biotechnology · 2020Article
- Discovery of an Unusual Fatty Acid Amide from theMarine drugs · 2018Article
- Identification of a butenolide signaling system that regulates nikkomycin biosynthesis inThe Journal of biological chemistry · 2018Article
- Regulation of antibiotic biosynthesis in actinomycetes: Perspectives and challenges.Synthetic and systems biotechnology · 2018Review
- Rational engineering of Streptomyces albus J1074 for the overexpression of secondary metabolite gene clusters.Microbial cell factories · 2018Article
- Precursor-directed combinatorial biosynthesis of cephalosporin analogue by endolithic actinobacterium3 Biotech · 2018Article
- Activation and mechanism of a cryptic oviedomycin gene cluster via the disruption of a global regulatory gene,The Journal of biological chemistry · 2017Article
- A New Dioic Acid from a wbl Gene Mutant of Deepsea-Derived Streptomyces somaliensis SCSIO ZH66.Marine drugs · 2016Article
- Activation of a plasmid-situated type III PKS gene cluster by deletion of a wbl gene in deepsea-derived Streptomyces somaliensis SCSIO ZH66.Microbial cell factories · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStreptomyces, as the main source of antibiotics, has been intensively exploited for discovering new drug candidates to combat the evolving pathogens. Disruption of wblA, an actinobacteria-specific gene controlling major developmental transition, can cause the alteration of phenotype and morphology in many species of Streptomyces. One wblA homologue was found in Streptomyces ansochromogenes 7100 by using the Basic Local Alignment Search Tool. It is interesting to identify whether novel secondary metabolites could be produced by the wblA disruption mutant as evidenced in other Streptomyces.
resultsThe wblA disruption mutant of S. ansochromogenes 7100 (ΔwblA) was constructed by homologous recombination. ΔwblA failed to produce spores and nikkomycin, the major product of S. ansochromogenes 7100 (wild-type strain) during fermentation. Antibacterial activity against Staphylococcus aureus and Bacillus cereus was observed with fermentation broth of ΔwblA but not with that of the wild-type strain. To identify the antibacterial compounds, the two compounds (compound 1 and compound 2) produced by ΔwblA were characterized as 16-membered macrolides by mass spectrometry and nuclear magnetic resonance spectroscopy. The chemical structure of these compounds shows similarity with tylosin, and the bioassays indicated that the two compounds inhibited the growth of a number of gram-positive bacteria. It is intriguing that they displayed much higher activity than tylosin against Streptococcus pneumoniae.
conclusionsTwo novel tylosin analogues (compound 1 and 2) were generated by ΔwblA. Bioassays showed that compound 1 and 2 displayed much higher activity than tylosin against Streptococcus pneumoniae, implying that these two compounds might be used to widen the application of tylosin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.